Awaiting development: Guidance and quality standards

Showing 111 to 120 of 373

Guidance and quality standards awaiting development
Title	Type
Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]	Technology appraisal guidance
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [ID6759]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]	Technology appraisal guidance
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Excimer Laser Trabeculotomy (ELT) for glaucoma	HealthTech guidance
Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]	Technology appraisal guidance